Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 47Carcinoma, Hepatocellular 29Neoplasms 18Neoplasm Metastasis 14Melanoma 14Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Triple Negative Breast Neoplasms 9Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Breast Neoplasms 8Rectal Neoplasms 7Pancreatic Neoplasms 7Lung Neoplasms 7Carcinoma, Renal Cell 7Biliary Tract Neoplasms 7Small Cell Lung Carcinoma 6Colonic Neoplasms 5Cholangiocarcinoma 5Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Immune Checkpoint Inhibitors × Clear all
NCT07570849 2026-05-06

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

Shanghai Zhongshan Hospital

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06505486 2024-07-17

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting
21 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05489692 2022-08-10

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Completed
43 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡